Pseudomonas aeruginosa is an opportunistic pathogen that may cause severe invasive diseases in critically ill patients. In the 21st century, when the life expectancy of highly susceptible immunocompromised groups has been extended in most countries, P. aeruginosa plays an increasingly prominent role in hospital infections. This organism shows a remarkable capacity to resist antibiotics, either intrinsically (because of constitutive expression of beta-lactamases and efflux pumps, combined with low permeability of the outer-membrane) or following acquisition of resistance genes (e.g., genes for beta-lactamases, or enzymes inactivating aminoglycosides or modifying their target), over-expression of efflux pumps, decreased expression of porins, or mutations in quinolone targets. These mechanisms mediate the multidrug-resistant (MDR) phenotype in P. aeruginosa.
Category
Infectious disease
Brite
Infectious diseases [BR:br08401]
Bacterial infections
Infections caused by other gamma proteobacteria
H00313 Multidrug-resistant Pseudomonas aeruginosa infection
Human diseases in ICD-11 classification [BR:br08403]
21 Symptoms, signs or clinical findings, not elsewhere classified
General symptoms, signs or clinical findings
Finding of microorganism resistant to antimicrobial drugs
MG50 Finding of gram negative bacteria resistant to antimicrobial drugs
H00313 Multidrug-resistant Pseudomonas aeruginosa infection
Pathogen
Pseudomonas aeruginosa [GN:pap pnc prp]
Comment
P. aeruginosa genes containing mutations:
nalC [KO:K18130]
nalD [KO:K18135]
Other DBs
ICD-11:
MG50.8
ICD-10:
A49.8 J15.1
MeSH:
D011552
Reference
PMID:20715920
Authors
Hirsch EB, Tam VH
Title
Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes.
Journal
Expert Rev Pharmacoecon Outcomes Res 10:441-51 (2010) DOI:10.1586/erp.10.49
Reference
PMID:17266725
Authors
Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F
Title
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.